Names and pronunciation
(ne-si-toom′oo-mab) Portrazza
PDF page 939
Loading InternPractice…
Drug reference
(ne-si-toom′oo-mab) Portrazza
PDF page 939
Func. class.: Antineoplastic agent, epidermal growth factor receptor (EGFR) inhibitor Func. class.: Antidepressant, SSRI
PDF page 939
USES: First-line treatment of meta- static squamous non-small cell lung can- cer (NSCLC) in combination with gem- citabine and cisplatin USES: Depression
PDF page 939
CONTRAINDICATIONS Hypersensitivity, pregnancy N
PDF page 939
Black Box Warning: Cardiopulmonary arrest, hypomagnesemia Black Box Warning: Suicidal thoughts, behaviors, children, young adults, hepatic failure Adult: PO Initial: 100 mg bid or 50-100 mg/day, then gradually increase by 100-200 mg/day (in 2 divided doses) and intervals ≥1 wk to a usual dose of 150-600 mg/day in 2 divided doses.
PDF pages 939, 940
DOSAGE AND ROUTES Non-small cell lung cancer (squa- mous), metastatic. Adult: IV: 800 mg on days 1 and 8 of each 3-wk treatment cycle (in combination with gem- citabine and cisplatin); continue until dis- ease progression or unacceptable toxicity DOSAGE AND ROUTES
PDF page 939
Available forms: 800 mg/50 mL solu- tion for injection (nef-ay′zoe-done) Available forms: Tabs 50, 100, 150, 200, 250 mg HIGH ALERT
PDF pages 939, 940